definiens: , as used in Section 2.2.2(a ) above, means achievement of positive results ( inclu ding, for example, in a Phase II Clinical Study ), a s determined by the Joint Steering Committee, that su pport the efficacy of Product for a Non - Epilepsy In dication and notwithstanding the foregoing, a Product for a Non - Epilepsy Indication will be deemed to have achi eved the milestone event in Section 2.2.2(a ) upon the enroll ment of the first patient in a Phase III Clinical S tudy for Product for such Non - Epilepsy Indication ; ( ii ) after the Effective Date, the Joint Steering Committee will reasonably determine whether the study design for t he * * * is appropriate to yield results that if posi tive would PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AN D EXCHANGE COMMISSION ( THE ) . THE OMISSIONS HAVE BEEN INDICATED BY ASTERISKS ( ), AND THE OMITTED TEXT HAS BEEN FILED SEPARATELY WITH THE COM MISSION